Hatch-Waxman ANDA litigation rankings covering brand and generic representation across the full lifecycle of Paragraph IV disputes. Built on PACER docket data, FDA Orange Book, and FDA approval records. The first edition publishes in 2026.
Methodology in draft. First edition: 2026.
Every signal is computed from PACER court records, FDA Orange Book patent listings, and FDA generic approval records. Brand and generic counsel are tracked separately, with 30-month stay clocks, settlement timing, and launch outcomes all extracted.
Six performance signals across both brand and generic representation. Hatch-Waxman has its own rhythm — Paragraph IV certifications, 30-month stays, settlement timing, at-risk launches — and signals reflect that.
Weighted participation across brand- and generic-side Paragraph IV disputes.
Win rates across Markman, dispositive motions, trial, and post-trial — on validity and infringement separately.
How counsel manages the statutory stay clock — settlement timing, MDL coordination, multi-defendant strategy.
Pre-trial settlement rate and the timing and structure of agreed entry dates and royalties.
Generic-side: launch authorization, 180-day exclusivity capture, at-risk launches and their outcomes.
Therapeutic area and molecule diversity — specialist versus generalist Hatch-Waxman practice.
Most rankings ask you to make a case for yourself. We already have the evidence.
When the first edition launches in 2026, firms and attorneys appearing in the Top 100 of any official category — brand or generic — will be eligible to license the LexDana ANDA Intelligence Badge.
Signal definitions, cohort normalization, weighting, and the exact data window — all published.
Methodology →